Your browser doesn't support javascript.
loading
Neutralizing antibody evasion and receptor binding features of SARS-CoV-2 Omicron BA.2.75
Yunlong Cao; Weiliang Song; Lei Wang; Pan Liu; Can Yue; Fanchong Jian; Yuanling Yu; Ayijiang Yisimayi; Peng Wang; Yao Wang; Qianhui Zhu; Jie Deng; Wangjun Fu; Lingling Yu; Na Zhang; Jing Wang; Tianhe Xiao; Ran An; Jing Wang; Lu Liu; Sijie Yang; Xiao Niu; Qingqing Gu; Fei Shao; Xiaohua Hao; Ronghua Jin; Youchun Wang; Xiaoliang Sunney Xie; Xiangxi Wang.
Affiliation
  • Yunlong Cao; Peking University
  • Weiliang Song; Biomedical Pioneering Innovation Center (BIOPIC), Peking University
  • Lei Wang; Chinese Academy of Sciences
  • Pan Liu; Chinese Academy of Sciences
  • Can Yue; University of Chinese Academy of Science
  • Fanchong Jian; Biomedical Pioneering Innovation Center (BIOPIC), Peking University
  • Yuanling Yu; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)
  • Ayijiang Yisimayi; Biomedical Pioneering Innovation Center (BIOPIC), Peking University
  • Peng Wang; Changping Laboratory, Beijing, P.R. China.
  • Yao Wang; Changping Laboratory, Beijing, P.R. China.
  • Qianhui Zhu; Chinese Academy of Sciences
  • Jie Deng; Chinese Academy of Sciences
  • Wangjun Fu; Chinese Academy of Sciences
  • Lingling Yu; Changping Laboratory, Beijing, P.R. China.
  • Na Zhang; Changping Laboratory, Beijing, P.R. China.
  • Jing Wang; Biomedical Pioneering Innovation Center (BIOPIC), Peking University
  • Tianhe Xiao; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.
  • Ran An; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China.
  • Jing Wang; Changping Laboratory, Beijing, P.R. China.
  • Lu Liu; Changping Laboratory, Beijing, P.R. China.
  • Sijie Yang; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China.
  • Xiao Niu; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China.
  • Qingqing Gu; Changping Laboratory, Beijing, P.R. China.
  • Fei Shao; Changping Laboratory, Beijing, P.R. China.
  • Xiaohua Hao; Beijing Ditan Hospital, Capital Medical University, Beijing, P.R. China.
  • Ronghua Jin; Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
  • Youchun Wang; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO
  • Xiaoliang Sunney Xie; Biomedical Pioneering Innovation Center (BIOPIC), Peking University
  • Xiangxi Wang; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P.R. China.
Preprint in English | bioRxiv | ID: ppbiorxiv-500332
ABSTRACT
Recently emerged SARS-CoV-2 Omicron subvariant, BA.2.75, displayed a local growth advantage over BA.2.38, BA.2.76 and BA.5 in India. The underlying mechanism of BA.2.75s enhanced infectivity, especially compared to BA.5, remains unclear. Here, we show that BA.2.75 exhibits substantially higher ACE2-binding affinity than BA.5. Also, BA.2.75 spike shows decreased thermostability and increased "up" RBD conformation in acidic conditions, suggesting enhanced low-pH-endosomal cell-entry pathway utilization. BA.2.75 is less humoral immune evasive than BA.4/BA.5 in BA.1/BA.2 breakthrough-infection convalescents; however, BA.2.75 shows heavier neutralization evasion in Delta breakthrough-infection convalescents. Importantly, plasma from BA.5 breakthrough infection exhibit significantly weaker neutralization against BA.2.75 than BA.5, mainly due to BA.2.75s distinct RBD and NTD-targeting antibody escaping pattern from BA.4/BA.5. Additionally, Evusheld and Bebtelovimab remain effective against BA.2.75, and Sotrovimab recovered RBD-binding affinity. Together, our results suggest BA.2.75 may prevail after the global BA.4/BA.5 wave, and its increased receptor-binding capability could allow further incorporation of immune-evasive mutations.
License
cc_by_nc_nd
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2022 Document type: Preprint
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2022 Document type: Preprint